Our results support a new treatment paradigm for T-ALL involving: (1) early genetic screening for the chemotherapy-refractory BMP-like phenotype and (2) clinical testing of BCL2 inhibitors in refractory BMP-like T-ALL. This evidence concerns the gene BCL2 and acute lymphoblastic leukemia.